110429-35-1

Basic information

• Product Name: PAROXETINE-D4 HCL
• Synonyms: Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate (2:1), (3S,4R)- (9CI);Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate (2:1), (3S-trans)-;Paroxetine Hydrochloride (350 mg);Paroxetine Hydrochloride (350 mg)G0D0030.972mg/mg(ai);Paroxetine-D4 hydrochloride;(3S,4R)-(-)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine Hydrochloride;Piperidine,3-[(1,3-benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate(2:2:1), (3S,4R)-;Paroxetine hydrochloride (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride
• CAS NO: 110429-35-1
• Molecular Formula: C₁₉H₂₀FNO₃*ClH
• Molecular Weight: 369.85
• Product Categories: Active Pharmaceutical Ingredients;Cnbio;Serotonin
• Mol File: 110429-35-1.mol
• Article Data: 26

Chemical Properties

• Melting Point: 121-131 C
• Boiling Point: 451.7oC at 760mmHg
• Flash Point: 227oC
• Appearance: white/
• Density: 1.213g/cm3
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol (96 per cent) and in methylene chloride.
• Merck: 14,7043
• CAS DataBase Reference: PAROXETINE-D4 HCL(CAS DataBase Reference)
• NIST Chemistry Reference: PAROXETINE-D4 HCL(110429-35-1)
• EPA Substance Registry System: PAROXETINE-D4 HCL(110429-35-1)

Safety Data

• Hazard Codes: F,C,Xn
• Statements: 11-34-36/37/38-22
• Safety Statements: 16-26-36/37/39-45-36
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• RTECS: TM4569320
• HazardClass: IRRITANT
• Hazardous Substances Data: 110429-35-1(Hazardous Substances Data)

Usage

Chemical Properties

White or almost white, crystalline powder.

Uses

Different sources of media describe the Uses of 110429-35-1 differently. You can refer to the following data:
1. Paroxetine Hydrochloride, is a selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat depression, panic attacks, obsessive-compulsive disorder (OCD), anxiety disorders, post-traumatic stress disorder, and a severe form of premenstrual syndrome (premenstrual dysphoric disorder).
2. Antidepressant;5-HT uptake inhibitor
3. Paroxetine hydrochloride hemihydrate has been used: as an antidepressant to study its effects on neural stem cells (NSCs) from embryonic rat hippocampus in vitro; as a CYP 2D6 inhibitor to study its effects on the in vitro?production by human recombinant CYP 2D6 of the phenolic metabolites; as an antidepressant to study its effects on the expression of pituitary adenylate cyclase activating polypeptide (PACAP), its receptors and brain-derived neurotrophic factor (BDNF) in rat primary hippocampal neurons

General Description

Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards

Biochem/physiol Actions

Paroxetine hydrochloride hemihydrate is one of the most potent and selective of the selective serotonin reuptake inhibitors (SSRI); antidepressant

InChI:InChI=1/C19H20FNO3.ClH/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;/h1-6,9,14,17,21H,7-8,10-12H2;1H/t14?,17-;/m0./s1

Upstream product

• 246850-71-5 (3S,4R)-trans-1-benzyloxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxyphenyl)oxymethyl]piperidine 
• 349446-96-4 {(3S,4R)-4-(p-fluorophenyl)-3-(hydroxymethyl)-1-[1-(S)-phenylethyl]}piperidine 
• 1381968-84-8 C₂₀H₃₁NO₃Si 
• 352-13-6 4-flourophenylmagnesium bromide 
• 5724-03-8 1-(4-fluorophenyl)allyl alcohol 
• 1561215-70-0 (3R,4S)-5-amino-4-((benzo[d][1,3]dioxol-5-yloxy)methyl)-3-(4-fluorophenyl)pentan-1-ol 
• 1561215-67-5 2-((2S,3R)-2-((benzo[d][1,3]dioxol-5-yloxy)methyl)-3-(4-fluorophenyl)-5-hydroxypentyl)isoindoline-1,3-dione 
• 1561215-69-7 2-((2S,3R)-2-((benzo[d][1,3]dioxol-5-yloxy)methyl)-3-(4-fluorophenyl)pent-4-en-1-yl)isoindoline-1,3-dione 
• 1561215-68-6 2-((2S,3R)-3-(4-fluorophenyl)-2-(hydroxymethyl)pent-4-en-1-yl)isoindoline-1,3-dione 
• 1561215-66-4 (2S,3R)-2-((1,3-dioxoisoindolin-2-yl)methyl)-3-(4-fluorophenyl)pent-4-enal 
• 110429-36-2 (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-1-methylpiperidine 
• 109887-52-7 C₁₅H₁₆FNO₄ 

Downstream Products

• 105813-14-7 (3S,4R)-1-benzyl-4-(4-fluorophenyl)-3-[3,4-(methylenedioxy)-phenoxymethyl]piperidine 
• 64006-44-6 paroxetine maleate 
• 606968-05-2 C₃₉H₄₀F₂N₂O₆ 

Relevant articles and documents

Diastereoconvergent Synthesis of (–)-Paroxetine

A diastereoconvergent approach to (–)-paroxetine from diastereomeric 3,4-epoxy-2-piperidones is reported. For this synthesis, a regioselective and stereodivergent CuI-catalyzed epoxide-ring-opening reaction of epoxyamide precursors to give the 4-(4-fluorophenyl)-2-piperidone skeleton with the correct absolute configuration is crucial. Using CuBr·SMe2 as a catalyst, the epoxide-ring-opening reaction takes place with inversion of configuration; the configuration is retained when CuI is used.

Improved process for paroxetine hydrochloride substantially free from potential impurities

An efficient process for production of paroxetine hydrochloride hemihydrate 1, a selective 5-hydroxytryptamine (serotonin) reuptake inhibitor, is described. Identification and control of potential impurities and establishment of efficient downstream workup procedures enabled us to produce paroxetine hydrochloride hemihydrate 1 efficiently.

Controlled Release Compositions of an Antidepressant Agent

The present invention relates to controlled release compositions comprising an anti-depressant compound. More particularly, the present invention relates to controlled release compositions comprising paroxetine hydrochloride.